Type of information: Development agreement
Compound: synthetic tissue-specific promoters for use in the specialised cells of the immune system
Company: Synpromics (UK) UCL Great Ormond Street Institute of Child Health (UK)
Therapeutic area: Cancer - Oncology - Immunological diseases
Type agreement: research - development
Action mechanism: gene therapy
Disease: pathologies affecting the haematopoietic system
- • On January 25, 2018, Synpromics Ltd, the leader in gene control, announces a collaboration with UCL Great Ormond Street Institute of Child Health, to develop novel gene therapies for pathologies affecting the haematopoietic system. This new partnership further expands Synpromics’ activities in the cell and gene therapy sector, as it builds on its strategy of establishing partnerships with leading academics in the UK to integrate its technology into the next generation of gene-based medicines.
- This research and development agreement with Professor Adrian Thrasher’s clinical research group at UCL Great Ormond Street Institute of Child Health, will develop synthetic tissue-specific promoters for use in the specialised cells of the immune system including lymphoid, myeloid and microglia cells.
- The objective of this work is to develop synthetic promoters that can be directly applied to gene-modified cell therapy, particularly where cells such as microglia or other myeloid cells can be used to deliver a therapeutic protein to the target pathologic sites. Similarly, output from the collaboration also has direct applications to further improve CAR-T therapy.
- Synpromics is expanding its commercial activities in the gene therapy sector by seeding the development of new candidate gene therapies for the treatment of numerous pathologies, where tight and effective regulation of gene expression is key to the success of the therapy. This collaboration heralds an important landmark in that development programme.